The Column Group, a private equity firm, led a $148m Series A funding round in Eikon Therapeutics, a biopharmaceutical and drug research company. Additional investors include Foresite Capital, Innovation Endeavors and Lux Capital. “Roger shares this passion for integrative science and building high-performing R&D organizations where diverse skill sets are honored and encouraged. On behalf of the entire team, we look forward to working with him to continue building an organization of interdisciplinary experts who share our commitment to developing new therapies for severe unmet health needs," Leon Chen, The Column Group Partner.